| Ge, Junbo |
NCT03008083: Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation |
|
|
| Recruiting | 4 | 2446 | RoW | 3 months DAPT, Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day), 12 months DAPT | Shanghai MicroPort Medical (Group) Co., Ltd. | Drug-Eluting Stents, Percutaneous Coronary Intervention | 12/20 | 10/22 | | |
CLEAN, NCT04665648: Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention |
|
|
| Recruiting | 4 | 1500 | RoW | Nicorandil, intraveous nicorandil, Placebo, intraveous palcebo | Fudan University | ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention | 08/24 | 12/24 | | |
NCT04135677: Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO |
|
|
| Recruiting | 4 | 826 | RoW | Rivaroxaban, new oral anticoagulation, DAPT, dual antiplatelet therapy | Shanghai Zhongshan Hospital | Left Atrial Appendage Thrombosis, Thrombi, Stroke | 10/24 | 10/24 | | |
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients |
|
|
| Recruiting | 4 | 2120 | RoW | Ticagrelor 60mg, Ticagrelor 90mg | Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University | Acute Coronary Syndrome, Coronary Stent Implantation | 12/24 | 12/24 | | |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/26 | 06/30 | | |
NCT05260411: A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia |
|
|
| Recruiting | 3 | 240 | RoW | AK102, Placebo | Akeso | Hyperlipidemia | 06/22 | 12/22 | | |
RECOVERII, NCT04571580: Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention |
|
|
| Terminated | 3 | 36 | RoW | Normal Saline, intracoronary normal saline, Reteplase Injection 9mg, intracoronary reteplase 9mg, Reteplase Injection 18mg, intracoronary reteplase 18mg | Ge Junbo | Acute ST-segment Elevation Myocardial Infarction | 01/23 | 01/23 | | |
| Active, not recruiting | 2 | 100 | RoW | Pirfenidone Oral Capsule, Placebo Oral Capsule | Shanghai Zhongshan Hospital, Beijing Continent Pharmaceutical Co, Ltd. | Myocardial Fibrosis | 05/24 | 06/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
NCT03466918: China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population |
|
|
| Active, not recruiting | N/A | 58 | RoW | SAPIEN 3 THV with the Commander delivery system | Edwards Lifesciences | Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation | 07/19 | 09/25 | | |
| Not yet recruiting | N/A | 616 | NA | intravascular ultrasound (IVUS), coronary angiography | Shanghai Zhongshan Hospital | Coronary Artery Disease, Left Main Coronary Artery Disease | 09/21 | 09/23 | | |
NCT04582877: Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial |
|
|
| Completed | N/A | 300 | RoW | FFR measurement | Zurich Medical Inc. | Myocardial Ischemia | 11/23 | 04/24 | | |
NCT03716011: A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT |
|
|
| Not yet recruiting | N/A | 2700 | RoW | EXCROSSAL | JW Medical Systems Ltd | Coronary Artery Disease | 12/21 | 12/25 | | |
NCT04414878: VitaFlowâ„¢ II Transcatheter Aortic Valve System Pre-market Trial |
|
|
| Recruiting | N/A | 145 | RoW | VitaFlowâ„¢ II Transcatheter Aortic Valve System | Shanghai MicroPort CardioFlow Medtech Co., Ltd. | Aortic Stenosis | 01/22 | 01/27 | | |
NCT04575012: Compare Early With Deferred Invasive Strategy for STEMI Presenting 24-48 Hours From Symptom Onset |
|
|
| Not yet recruiting | N/A | 1200 | NA | Deferred invasive strategy, Early invasive strategy | Shanghai Zhongshan Hospital | ST-segment Elevation Myocardial Infarction (STEMI) | 12/22 | 12/25 | | |
NCT05391191: Safety and Feasibility of TRISKELE in Severe AS |
|
|
| Recruiting | N/A | 7 | RoW | MitrAssist TRISKELE® transcatheter aortic valve system | Shanghai Zhongshan Hospital | Aortic Valve Disease | 03/23 | 03/23 | | |
| Recruiting | N/A | 30 | RoW | FreeFlow percutaneous atrial septal shunt | Shanghai Zhongshan Hospital | Pulmonary Arterial Hypertension | 09/27 | 09/27 | | |
| Recruiting | N/A | 2132 | RoW | caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve | Peking University First Hospital, Rainmed Ltd., Suzhou, China | Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention | 12/23 | 12/25 | | |
NCT03714802: Modified T-Stenting With Szabo Technique Versus T-Stenting for Bifurcation Lesions in Coronary Heart Diseases |
|
|
| Recruiting | N/A | 100 | RoW | Szabo T-Stenting Technique, T-Stenting Technique | Shanghai Zhongshan Hospital | Coronary Artery Disease | 12/23 | 12/24 | | |
| Recruiting | N/A | 200 | RoW | Oral apixaban | Shanghai Zhongshan Hospital | Evaluate the Safety and Efficacy of Apixaban | 12/23 | 12/24 | | |
NCT06110988: A Clinical Study for the Pan-vascular Interventional Robotic System |
|
|
| Not yet recruiting | N/A | 5 | RoW | Pan-vascular interventional robotic system | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention, Pan-vascular Interventional Robotic System | 09/24 | 09/24 | | |
NCT06213714: The 5th Generation Tele-Robotic-Assisted Percutaneous Coronary Intervention: A First-in-Human Trial |
|
|
| Not yet recruiting | N/A | 12 | NA | 5G Tele-Robotic-Assisted PCI, VRS100 Robotic Console System | Yan'an Affiliated Hospital of Kunming Medical University, Shanghai Zhongshan Hospital, Kunming Chenggong District People's Hospital | Coronary Artery Disease, Myocardial Ischemia, Cardiovascular Diseases, Coronary Disease, Arteriosclerosis | 06/24 | 09/24 | | |
NCT03736226: A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China |
|
|
| Active, not recruiting | N/A | 2000 | RoW | SYNERGYTM Stent System | Boston Scientific Corporation | Cardiovascular Diseases | 08/24 | 03/28 | | |
NCT06502938: A Clinical Trial Evaluating the Pan-vascular Interventional Robotic System for Panvascularization Interventional Surgery |
|
|
| Not yet recruiting | N/A | 159 | RoW | Pan-vascular interventional robotic system, Traditional artificial percutaneous coronary intervention | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention | 07/25 | 12/25 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
NCT06032572: Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) |
|
|
| Not yet recruiting | N/A | 204 | RoW | VRS100 robotic-assisted PCI, Manual PCI | Shenzhen Raysight Intelligent Medical Technology Co., Ltd., Shanghai Zhongshan Hospital, West China Hospital, Shenzhen People's Hospital | Coronary Artery Disease, Cardiovascular Diseases, Coronary Disease, Myocardial Ischemia, Arteriosclerosis, Vascular Disease Occlusive | 08/24 | 08/24 | | |
| Not yet recruiting | N/A | 100 | RoW | computed tomography myocardial perfusion, Invasive Coronary Angiography | Shanghai Zhongshan Hospital | Non-ST Elevation Myocardial Infarction | 02/25 | 02/26 | | |
VITAL, NCT05813704: Coronary Crossing System in Patients With Coronary Chronic Total Occlusions |
|
|
| Recruiting | N/A | 156 | RoW | Coronary Crossing System of Shanghai MicroPort Rhythm | Shanghai MicroPort Rhythm MedTech Co., Ltd., Shanghai Zhongshan Hospital, Xiamen Cardiovascular Hospital, Xiamen University, Shanghai Baoshan District Wusong Central Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Wenzhou Medical University, Tianjin First Central Hospital, The Affiliated Hospital Of Southwest Medical University, Hebei General Hospital, West China Hospital, First Affiliated Hospital of Army Medical University, PLA, Lanzhou University First Hospital, Nanfang Hospital, Southern Medical University, The Second Affiliated Hospital of Dalian Medical University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Chronic Total Occlusion of Coronary Artery | 04/25 | 05/25 | | |
CONFIDENT, NCT05857904: Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain |
|
|
| Not yet recruiting | N/A | 4648 | RoW | CT-FFR, QFR | Shanghai Zhongshan Hospital | Angina, Stable, Coronary Artery Disease | 05/25 | 05/28 | | |
NCT05947448: Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study |
|
|
| Recruiting | N/A | 1215 | RoW | Azilsartan Medoxomil Potassium Tablet, Nifedipine Sustained -release Tablets, Levoamlodipine Maleate Table | Hasten Biopharmaceutical Co., Ltd. | Essential Hypertension | 06/25 | 12/25 | | |
| Recruiting | N/A | 5000 | RoW | Coronary CT angiography | Shanghai Zhongshan Hospital | Coronary Artery Disease | 12/25 | 12/30 | | |
NCT05194423: THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein |
|
|
| Recruiting | N/A | 150 | RoW | Tricuspid Valve Replacement System via jugular vein | Changhai Hospital, Shanghai Zhongshan Hospital, Fu Wai Hospital, Beijing, China, Beijing Anzhen Hospital, Wuhan Union Hospital, China, West China Hospital, Xijing Hospital, Guangdong Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University | Tricuspid Valve Regurgitation | 03/27 | 03/27 | | |
| Recruiting | N/A | 10000 | RoW | | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Artery Disease | 12/32 | 12/33 | | |
| Not yet recruiting | N/A | 271 | RoW | Angiography-drived Index of Microcirculatory Resistance, Angio-IMR, CaIMR | Shanghai Zhongshan Hospital, Shanghai 10th People's Hospital | Coronary Microvascular Dysfunction, Myocardial Ischemia | 05/21 | 10/21 | | |
CHART-OPTIMIZE, NCT05125107: PrOgnostic imPlicaTIons of 2-diMensIonal Patterns for Residual Disease After Stenting CharacteriZEd by Quantitative Flow Ratio Pullback Curve Analysis |
|
|
| Not yet recruiting | N/A | 1607 | NA | Quantitative Flow Ratio derived PPG and dQFR/ds | Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital | Coronary Artery Disease | 12/21 | 03/22 | | |
CHART-ORIGIN, NCT05104580: PrOgnostic Implications of PRe-stent Pullback Pressure GradIent and Post-stent Quantitative Flow Ratio in Patients UnderGoing Percutaneous Coronary INtervention |
|
|
| Not yet recruiting | N/A | 1395 | NA | Quantitative Flow Ratio derived PPG | Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital | Coronary Artery Disease | 01/22 | 03/22 | | |
| Recruiting | N/A | 378 | RoW | Coronary CTA | Shanghai Zhongshan Hospital | Coronary Artery Disease | 04/22 | 05/22 | | |
| Recruiting | N/A | 329 | RoW | Percutaneous coronary intervention | Shanghai Zhongshan Hospital | Coronary Artery Disease | 08/22 | 10/22 | | |
NCT04518826: A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES |
|
|
| Not yet recruiting | N/A | 420 | NA | fractional flow reserve | Shanghai Zhongshan Hospital | In Stent Restenosis, Drug Eluting Stent, Coronary Artery Disease | 10/22 | 10/24 | | |
| Recruiting | N/A | 300 | RoW | CCTA and 18F-FDG-PET/CT | Shanghai Zhongshan Hospital | Coronary Artery Disease | 10/22 | 12/22 | | |
